共 72 条
[1]
Shien K(2013)Acquired resistance to EGFR inhibitors is associated with a manifestation of stem cell-like properties in cancer cells Cancer Res 73 3051-3061
[2]
Toyooka S(2012)A common BIM deletion polymorphism mediates intrinsic resistance and inferior responses to tyrosine kinase inhibitors in cancer Nat Med 18 521-528
[3]
Yamamoto H(2013)Erlotinib versus docetaxel as second-line treatment of patients with advanced non-small-cell lung cancer and wild-type EGFR tumours (TAILOR): a randomised controlled trial Lancet Oncol 14 981-988
[4]
Ng KP(2012)Targeting triple-negative breast cancer cells with the histone deacetylase inhibitor panobinostat Breast Cancer Res 14 R79-950
[5]
Hillmer AM(2006)Restoring E-cadherin expression increases sensitivity to epidermal growth factor receptor inhibitors in lung cancer cell lines Cancer Res 66 944-2524
[6]
Chuah CT(2007)Effect of the histone deacetylase inhibitor LBH589 against epidermal growth factor receptor-dependent human lung cancer cells Mol Cancer Ther 6 2515-2434
[7]
Garassino MC(2013)EGFR-TKI resistance due to BIM polymorphism can be circumvented in combination with HDAC inhibition Cancer Res 73 2428-2282
[8]
Martelli O(2012)Complex role of histone deacetylase inhibitors in the treatment of non-small-cell lung cancer J Clin Oncol 30 2280-199
[9]
Broggini M(2014)Vorinostat and bortezomib as third-line therapy in patients with advanced non-small cell lung cancer: a wisconsin oncology network phase II study Invest New Drugs 32 195-247
[10]
Tate CR(2009)New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1) Eur J Cancer 45 228-1500